Agenus to Present at OneMedForum San Francisco 2013

Wed Jan 2, 2013 3:53pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130102:nGNXUWWWKa

LEXINGTON, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of
therapeutic vaccines for cancer and infectious diseases, today announced that the company will be
presenting at the 6th Annual OneMedForum San Francisco 2013, which will be held at the Sir Francis
Drake Hotel in San Francisco.

Dr. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview on Tuesday, January
8th at 9:40 am PST in the Franciscan Room.

Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon®
adjuvant1 is being studied in clinical trials for 17 vaccine indications. They include:

* Phase 3: GSK's RTS,S for malaria2
* Phase 3: GSK's MAGE-A3 for non-small cell lung cancer2
* Phase 3: GSK's MAGE-A3 for melanoma2
* Phase 3: GSK's Zoster Herpes for shingles2
* Phase 2: Janssen's ACC-001 for Alzheimer's disease

Agenus pipeline programs include:

* Phase 2: Prophage Series G-100 for newly diagnosed glioma
* Phase 2: Prophage Series G-200 for recurrent glioma
* Phase 2 : HerpV (contains QS-21 Stimulon) for genital herpes

Saponin Platform: QS-21 Stimulon

®

Adjuvant

Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally
entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties
for 10 years after commercial launch, with some exceptions.

Heat Shock Protein Platform: Prophage Series G

The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two different settings of
glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with
an average survival of six to 14 months.

Heat Shock Protein Platform: Recombinant Series HerpV

HerpV is the most advanced HSV-2 vaccine currently in clinical development for the treatment of
genital herpes. A Phase 2 study measuring the effect of vaccination on viral shedding in
individuals infected with HSV-2 is underway. Data results for this study are anticipated in Q4'13.
Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into
the clinical benefit of a reduction in recurrent outbreaks.

Web Cast Information                                                                              
    

The live and archived webcast of the company presentation will be accessible from the company's
website at www.agenusbio.com/webcast
http://www.globenewswire.com/newsroom/ctr?d=10016901&l=12&a=www.agenusbio.com%2Fwebcast&u=http%3A%2F%2Fwww.agenusbio.com%2Fwebcast
. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The
archived replay will be available on the Agenus website for one month following the conference.

About Agenus

Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious
diseases. The company is focused on immunotherapeutic products based on strong platform
technologies with multiple product candidates advancing through the clinic, including several
product candidates that have advanced into late-stage clinical trials through corporate partners.
For more information, please visit www.agenusbio.com
http://www.globenewswire.com/newsroom/ctr?d=10016901&l=14&a=www.agenusbio.com&u=http%3A%2F%2Fwww.agenusbio.com%2F
.

The Agenus logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8187
http://www.globenewswire.com/newsroom/ctr?d=10016901&l=15&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D8187


Forward-Looking Statement                                  

This press release contains forward-looking statements, including statements regarding up-coming
presentations and technologies, programs, and activities of the company and its licensees. These
forward-looking statements are subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among others, the factors described
under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended September 30, 2012. Agenus cautions investors not to
place considerable reliance on the forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus undertakes no obligation to
update or revise the statements. All forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus' business is subject to substantial risks and
uncertainties, including those identified above. When evaluating Agenus' business and securities,
investors should give careful consideration to these risks and uncertainties.

1. QS-21 Stimulon adjuvant and the related agreements, and HerpV are assets of Antigenics Inc., a
wholly owned subsidiary of Agenus Inc.
2. QS-21 is a component of GSK adjuvant systems.

Stimulon is a registered trademark of Agenus Inc. and its subsidiaries.

CONTACT: Media and Investor Contact:
         Jonae R. Barnes
         Vice President
         Investor Relations and
         Corporate Communications
         jonae.barnes@agenusbio.com
         617-818-2985
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.